世界中医药

目的：通过对肝癌前病变大鼠予抗纤抑癌方灌胃给药，结合肝脏病理及相关指标的免疫组化检测，观察抗纤抑癌方对肝癌前病变的治疗作用。方法：将55只Wistar雄性大鼠随机分为正常组10只、模型组15只、扶正化瘀组15只与抗纤抑癌组15只，除正常组外，其余各组以二乙基亚硝胺腹腔注射诱导肝癌前病变形成，每周1次，持续14周，同时每天分别以等计量生理盐水、扶正化瘀胶囊及抗纤抑癌颗粒的水溶剂灌胃给药，在第14周末给药后取材，进行大鼠肝脏HE、Masson病理染色及FN、GST-Pi及PCNA指标的免疫组化检测。结果：通过肝脏HE及Masson染色发现抗纤抑癌方较扶正化瘀胶囊可明显改善肝癌前病变大鼠肝脏纤维堆积及肝细胞异常增生情况，免疫组化结果显示抗纤抑癌方可明显减少肝癌前病变时FN、GST-Pi及PCNA表达（均为P<0.01），较扶正化瘀组也有较明显的改善作用（分别为P<0.01、P<0.01及P<0.05）。结论：抗纤抑癌方具有改善肝癌前病变大鼠肝脏纤维堆积及肝细胞异常增生等作用，其作用机制有待进一步深入研究。

English Summary:

To observe the efficacy of Kangxian Yi’Ai formula on liver precancerous lesions through immunohistochemistry test by gastric administration in rats.Methods：To randomly divide 55 male Wistar rats into four groups： 10 in the normal group， 10 in the model group， 15 in the Fuzheng Huayu capsule group and 15 in the Kangxian Yi’ai formula group respectively. Diethylnitrosamine had been given to induce liver precancerous lesions in all groups except the normal group for 14 weeks， once a week. Meanwhile， besides the normal group， saline， Fuzheng Huayu capsule and Kangxian Yi’ai fomula were also given the same dosage at each time in respective groups. At the end of the 14th week， tissues were taken to test the pathology of the liver， together with the IHC index included GST-Pi， PCNA and FN. Results： The liver HE and Masson staining showed that Kangxian Yi’ai formula could reduce the cirrhosis degree and the size of lesions much obviously than Fuzheng Huayu capsule did. In addition， the Kangxian Yi’Ai formula could reduced the FN， GST-Pi and PCNA much greatly than the control group (P<0.05) and the Fuzheng Huauu group (P<0.01， P<0.01 and P<0.05). Conclusion： Kangxian Yi’ai formula could constrain cirrhosis and the liver precancerous lesions induced by diethylnitrosamine in rats， but its mechanism is yet to be found.

查看全文查看/发表评论下载PDF阅读器